Aerobic Training in Metastatic Breast Cancer

Exclusion Criteria

• •Able to achieve an acceptable peak baseline CPET, as defined by any of the following criteria:
• •1. Achieving a plateau in oxygen consumption, concurrent with an increase in power output;
• •2. A respiratory exchange ratio ≥ 1.10;
• •3. Attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax \[HRmax = 220-Age\[years\]);
• •4. Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale
• •Normal cardiac function (left ventricular ejection fraction ≥50%);
• •Medical clearance from attending oncologist indicating no relative contraindications to undergo a symptom-limited cardiopulmonary exercise test and aerobic training intervention;
• •Patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be enrolled
• •Willing to be randomized to one of the study arms
• •Female
• •Any of the following absolute contraindications to cardiopulmonary exercise testing:
• •1. Acute myocardial infarction within 3-5 days of any planned study procedures
• •2. Unstable angina
• •3. Uncontrolled arrhythmia causing symptoms or hemodynamic compromise;
• •4. Recurrent syncope
• •5. Active endocarditis;
• •6. Acute myocarditis or pericarditis
• •7. Symptomatic severe aortic stenosis
• •8. Uncontrolled heart failure
• •9. Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures
• •10. Thrombosis of lower extremities
• •11. Suspected dissecting aneurysm
• •12. Uncontrolled asthma
• •13. Pulmonary edema
• •14. Room air desaturation at rest ≤ 85%
• •15. Respiratory failure
• •16. Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)
• •17. Mental impairment leading to inability to cooperate.
• •Any other condition or intercurrent illness that, in the opinion of the investigator, makes the participant a poor candidate for the trial
• •Presence of extensive skeletal metastases, defined as more than five (5) sites of bony disease, or any symptomatic site of disease in the spine, hip, or femur. Note that, patients with more than five bony sites may be deemed eligible at the discretion of the attending oncologist.